Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLoans - Loss AllowanceLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innate Pharma (IPHA) Short term Debt (2017 - 2025)

Historic Short term Debt for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to $10.1 million.

  • Innate Pharma's Short term Debt rose 517.29% to $10.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $10.1 million, marking a year-over-year increase of 517.29%. This contributed to the annual value of $9.4 million for FY2024, which is 248.44% down from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Short term Debt is $10.1 million, which was up 517.29% from $9.3 million recorded in Q4 2024.
  • Innate Pharma's 5-year Short term Debt high stood at $35.2 million for Q4 2021, and its period low was $2.1 million during Q4 2022.
  • Moreover, its 5-year median value for Short term Debt was $9.6 million (2023), whereas its average is $13.0 million.
  • Over the last 5 years, Innate Pharma's Short term Debt had its largest YoY gain of 127730.66% in 2021, and its largest YoY loss of 9988.06% in 2021.
  • Innate Pharma's Short term Debt (Quarter) stood at $35.2 million in 2021, then crashed by 93.9% to $2.1 million in 2022, then soared by 348.33% to $9.6 million in 2023, then fell by 3.21% to $9.3 million in 2024, then grew by 8.67% to $10.1 million in 2025.
  • Its Short term Debt stands at $10.1 million for Q2 2025, versus $9.3 million for Q4 2024 and $9.6 million for Q2 2024.